Interestingly, even if tofacitinib is the only FDA-approved drug indirectly related to the STAT3 target, it is still more effective than most of these first-line drugs for RA patients, especially in patients with methotrexate-resistant active RA. This evidence concerns the gene STAT3 and rheumatoid arthritis.